Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Abionyx Pharma SA currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct art units, which indicates that the company's pharmaceutical innovations are being evaluated by different specialized technical groups. The involvement of 3 distinct examiners across these 4 pending office actions suggests variety in the prosecution experience for the company.
AUDET, MAURY A is the busiest examiner for this entity, currently handling 2 pending office actions. This concentration represents 2 of the 4 pending office actions, making his examination style a factor in the overall success of the portfolio. The remaining actions are handled by the other 3 distinct examiners, requiring the company to adapt to different individual preferences within the Biotechnology & Pharmaceuticals sector. Practitioners should monitor the 2 distinct art units closely to ensure that arguments remain consistent even when presented to different examiners with potentially different perspectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
| No statute on record | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AUDET, MAURY A | 2 | 50.1% | +23.9% |
| LIEB, JEANETTE M | 1 | 79.8% | +17.4% |
| KOSAR, AARON J | 1 | 71.3% | +29.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854185 | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES | LIEB, JEANETTE M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854185 | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES | LIEB, JEANETTE M | — |
| 18854155 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | AUDET, MAURY A | — |
| 18554688 | USE OF LIPID BINDING PROTEIN-BASED COMPLEXES IN ORGAN PRESERVATION SOLUTIONS | KOSAR, AARON J | — |
| 18247465 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854185 | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES | LIEB, JEANETTE M | — | §102§103§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18854155 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | AUDET, MAURY A | — | Other | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18554688 | USE OF LIPID BINDING PROTEIN-BASED COMPLEXES IN ORGAN PRESERVATION SOLUTIONS | KOSAR, AARON J | 1655 | — | Non-Final OA | — | Pending | Oct 10, 2023 |
| 18247465 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | AUDET, MAURY A | 1654 | §103 | Final Rejection | — | Pending | Mar 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAbionyx Pharma SA has 4 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Maury A Audet has the most, with 2 of Abionyx Pharma SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
